Patient characteristics
| . | Overall (N = 167) . |
|---|---|
| Age, y | |
| Median | 53 |
| Range | 18-65 |
| Sex | |
| Male | 93 (55.7) |
| Baseline diagnosis | |
| AML, MDS | 74 (44.3) |
| MPN | 4 (2.4) |
| ALL | 10 (6.0) |
| Lymphoproliferative disease/CLL | 60 (35.9) |
| MM | 9 (5.4) |
| Other | 10 (6.0) |
| Disease Risk Index | |
| Low/moderate | 122 (73) |
| High/very high | 39 (23.4) |
| Not applicable* | 6 (3.6) |
| HCT-CI score | |
| <3 | 135 (80.8) |
| ≥3 | 32 (19.2) |
| EBMT score | |
| <5 | 153 (91.6) |
| ≥5 | 14 (8.4) |
| Conditioning regimen intensity | |
| MAC | 38 (22.8) |
| RIC | 129 (77.2) |
| GVHD prophylaxis | |
| ATG based | 22 (13.2) |
| PTCY based | 75 (44.9) |
| Sirolimus-tacrolimus | 19 (11.4) |
| MTX-CNI | 51 (30.5) |
| Donor type | |
| 10/10 MRD | 53 (31.7) |
| 10/10 and 9/10 MUD | 45 (26.9) |
| Haploidentical | 64 (38.3) |
| Dual (haploidentical + cord blood) | 5 (3) |
| Stem cell source | |
| Peripheral blood | 155 (92.8) |
| Bone marrow | 12 (7.2) |
| Follow-up in survivors, mo | |
| Median | 21.1 |
| Range | 3.8-70.8 |
| EASIX result | |
| EASIX-PRE | |
| Median | 1.073 |
| Range | 0.142-78.600 |
| 25th percentile | 0.719 |
| 75th percentile | 2.795 |
| Log2-EASIX-PRE | |
| Median | 0.102 |
| Range | −2.814 to 6.296 |
| 25th percentile | −0.474 |
| 75th percentile | 1.483 |
| . | Overall (N = 167) . |
|---|---|
| Age, y | |
| Median | 53 |
| Range | 18-65 |
| Sex | |
| Male | 93 (55.7) |
| Baseline diagnosis | |
| AML, MDS | 74 (44.3) |
| MPN | 4 (2.4) |
| ALL | 10 (6.0) |
| Lymphoproliferative disease/CLL | 60 (35.9) |
| MM | 9 (5.4) |
| Other | 10 (6.0) |
| Disease Risk Index | |
| Low/moderate | 122 (73) |
| High/very high | 39 (23.4) |
| Not applicable* | 6 (3.6) |
| HCT-CI score | |
| <3 | 135 (80.8) |
| ≥3 | 32 (19.2) |
| EBMT score | |
| <5 | 153 (91.6) |
| ≥5 | 14 (8.4) |
| Conditioning regimen intensity | |
| MAC | 38 (22.8) |
| RIC | 129 (77.2) |
| GVHD prophylaxis | |
| ATG based | 22 (13.2) |
| PTCY based | 75 (44.9) |
| Sirolimus-tacrolimus | 19 (11.4) |
| MTX-CNI | 51 (30.5) |
| Donor type | |
| 10/10 MRD | 53 (31.7) |
| 10/10 and 9/10 MUD | 45 (26.9) |
| Haploidentical | 64 (38.3) |
| Dual (haploidentical + cord blood) | 5 (3) |
| Stem cell source | |
| Peripheral blood | 155 (92.8) |
| Bone marrow | 12 (7.2) |
| Follow-up in survivors, mo | |
| Median | 21.1 |
| Range | 3.8-70.8 |
| EASIX result | |
| EASIX-PRE | |
| Median | 1.073 |
| Range | 0.142-78.600 |
| 25th percentile | 0.719 |
| 75th percentile | 2.795 |
| Log2-EASIX-PRE | |
| Median | 0.102 |
| Range | −2.814 to 6.296 |
| 25th percentile | −0.474 |
| 75th percentile | 1.483 |
Data are presented as n (%) unless otherwise indicated.
ALL, Acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; CLL, chronic lymphoid leukemia; CNI, calcineurin inhibitor; EBMT, European Group for Blood and Marrow Transplantation; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; PTCY, posttransplantation cyclophosphamide.
Disease Risk Index not calculated in 6 patients because they had nonmalignant disease.